Autolus Therapeutics Announces Initiative to Support Operational Efficiency and Cost Reduction
Autolus Therapeutics announced a strategic restructuring to improve operational efficiency, reducing its workforce by approximately 13% to cut costs while doubling manufacturing capacity for its commercial product in 2026. The company reiterated its full-year 2026 revenue guidance for AUCATZYL of $120 million to $135 million, up from $74 million in 2025, and expects to shift to a positive gross margin this year.
Key figures
- Guidance
- FY2026 AUCATZYL net product revenue $120 million to $135 million
- Cash runway
- fourth quarter of 2027
- Annualized savings
- $15 million
- Restructuring charges
- $8 million
- Headcount reduction pct
- 13%
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.